PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics announces an agreement with the Society of Gynecologic Oncology (SGO) to strategically help fund and support the SGO Research Institute Registry, an outcomes-focused research venue that aspires to bridge existing gaps within the field of gynecologic oncology. The registry is primarily centered on quality outcome and comparative effectiveness, clinical innovations, and cancer survivorship in women’s cancers and will include Precision’s first commercial test, ChemoFx®, a proprietary drug response marker which measures an individual’s malignant tumor response to a range of standard therapeutic alternatives in gynecologic cancers.
“Precision Therapeutics’ support of this registry is going to help us determine the best possible treatment for gynecologic malignancies, and by partnering with us over a period of time, we look forward to gathering enough data to make a significant impact in best practices for our subspecialty.”
Recent studies have shown that ChemoFx®can identify platinum-resistant/refractory primary ovarian patients, helping physicians in the selection of effective treatment upfront for patients newly diagnosed. Studies have also shown a 14 month (65%) improvement in overall survival (OS) and improved progression free survival (PFS) when recurrent ovarian cancer patients are treated with responsive therapies as indicated by ChemoFx.®
“With the creation of the SGO Research Institute Registry, we are now in a position to collect data and establish baseline performance levels that will ultimately enhance the quality of care for women with gynecologic cancers,” said SGO president Barbara A. Goff, MD. “Precision Therapeutics’ support of this registry is going to help us determine the best possible treatment for gynecologic malignancies, and by partnering with us over a period of time, we look forward to gathering enough data to make a significant impact in best practices for our subspecialty.”
Sean McDonald, President and CEO of Precision, stated that the registry, which the Society of Gynecologic Oncology (SGO) developed and Precision helps support, will enable the study of quality of life factors and patient outcomes throughout the continuum of each gynecologic patient’s cancer care.
“Precision has been working with the Society of Gynecologic Oncology to enhance research and development in gynecologic cancers for over a decade,” said Mr. McDonald. “We are thrilled to partner with the SGO in the development of tools that will support the specialty of gynecological cancer and augment innovation in the treatment of this disease, with the ultimate goal of improving outcomes and quality of life for gynecologic cancer patients.”
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to utilizing precision medicine for personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s leading products for personalized cancer care include:
- ChemoFx® Drug Response Assay, which can identify platinum-resistant/refractory primary ovarian patients, helping physicians in the selection of effective treatment upfront for patients newly diagnosed. Studies have also shown a 14 month (65%) improvement in overall survival (OS) and 50% improvement in progression free survival (PFS) when recurrent ovarian cancer patients are treated with responsive therapies as indicated by ChemoFx®.
- BioSpeciFx®, a select portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis.
- Precision also offers the microRNA-based Rosetta miRview® mets2 Tumor of Origin test, which Identifies 42 tumor origins with overall specificity up to 99% and overall sensitivity up to 85%.
Precision Therapeutics currently receives ChemoFx® specimens from over 270 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. Over 24,000 Gynecologic specimens have been submitted for ChemoFx® testing since 2011 from over 1,500 different doctors.
Additionally, in 2013 Precision plans to release two new genomic products that examine a patient’s tumor at the molecular level in order to garner information about a patient’s individual disease and potentially inform effective treatment options, under the GeneFx® brand. For more information, visit: www.precisiontherapeutics.com or www.chemofx.com.
About the Society of Gynecologic Oncology
The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women’s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations.
SGO has more than 1,700 members representing the entire gynecologic oncology team in the United States and abroad. Members include primarily gynecologic oncologists, as well as medical oncologists, pathologists, radiation oncologists, hematologists, surgical oncologists, obstetrician/gynecologists, nurses, physician assistants, social workers, fellows-in-training, residents and other allied health care professionals interested in the treatment and care of women’s cancer. SGO members provide multidisciplinary cancer treatment including chemotherapy, radiation therapy, surgery and supportive care. They practice in a variety of settings, including academic institutions and hospitals, major regional cancer centers and private practice. For more information visit: https://www.sgo.org/about-sgo/